Ramipril is an angiotensin converting enzyme (ACE) inhibitor, which after hydrolysis to ramiprilat, blocks the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. So, inhibition of ACE by ramipril results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion. Thus ramipril exerts its antihypertensive activity. It is also effective in the management of heart failure and reduction of the risk of stroke, myocardial infarction and death from cardiovascular events. It is long acting and well tolerated; so, can be used in long term therapy.
Ramace Tablet 5 mg
Adult: Initially, 2.5 mg once daily, 1st dose preferably given at bedtime. Maintenance: 2.5-5 mg daily as a single dose, up to 10 mg/day as needed.
Adult: Initially, 1.25 mg once daily. Max: 10 mg/day. Doses ≥2.5 mg may be given in single or 2 divided doses.
Adult: Initially, 2.5 mg bid, may increase to 5 mg bid after 2 days. Start treatment: 3-10 days after infarction. Maintenance: 2.5-5 mg bid.
Prophylaxis of cardiovascular events in high-risk patients:
Adult: Initially, 2.5 mg once daily, may increase to 5 mg once daily after 1 wk if tolerated. Maintenance: 10 mg once daily after a further 3 wk.